BIRFUTAMIG
UNII J9F7QYT6VW
Substance Identification & Data
This profile provides standardized clinical and technical data for Birfutamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) J9F7QYT6VW.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3080184-95-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
J9F7QYT6VW
3080184-95-5
N/A
Detailed Substance Profile
Preferred Name
BIRFUTAMIG
Official standardized name for this substance within the FDA UNII nomenclature system.
INN ID
14138
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Birfutamig
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Birfutamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Birfutamig
Common Names & Synonyms
Immunoglobulin G1, bispecific, [477-serine,491-alanine,492-alanine,522-alanine,586-alanine,623-tryptophan,611-cysteine], anti-(human/Macaca fascicularis G protein-coupled receptor GPRC5D) (human-Mus musculus monoclonal Bi-29H6-6 Fab fragment) fusion protein with immunoglobulin anti-(human/Macaca fascicularis CD3 antigen) (human-Mus musculus monoclonal Bi-29H6-6 single-chain variable fragment VH-(GGGGS)3-VL) fusion protein with immunoglobulin (human γ1-chain C region C-terminal fragment), (483→228′),(486→231′),(611→351′)-tris(disulfide) with immunoglobulin G1 [236′-alanine,237′-alanine,267′-alanine,331′-alanine,351′-cysteine,368′-serine,370′-alanine,409′-valine] anti-(human/Macaca fascicularis G protein-coupled receptor GPRC5D) (human-Mus musculus monoclonal Bi-29H6-6 γ1-chain), (222→220′′′),(222′→220′′)-bis(disulfide) with human-Mus musculus monoclonal Bi-29H6-6 κ-chain
birfutamig (immunoglobulin (H-gamma1_L-kappa)_(VH-G1(CH1-5h)-scFvhl-G1(h-CH2-CH3)_L-kappa), anti-[Homo sapiens GPRC5D (G protein-coupled receptor class C group 5 member D)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], monoclonal antibody, bispecific, trivalent)
birfutamig [INN]
heavy chain H-gamma1 anti-GPRC5D (hole) (H) (1-449) [VH Musmus/Homsap (Mus musculus IGHV1-47-14*01 (83.7%) -(IGHD) -IGHJ3*01 (91.7%) A128>S (119)/Homo sapiens IGHV1-46*01 (78.6%) -(IGHD) -IGHJ4*01 (100%), CDR -IMGT [8.8.12] (26-33.51-58.97-108)) (1-119) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, 1-G1v66 CH2 A27, 6-G1v14-4 CH2 A1.3, A1.2, A114, 14-G1v75 CH3 C5, 14-G1v33 CH3 S22, A24, V86 (hole) (CH1 K120 (216) (120-217), hinge 1-15 (218-232), CH2 L1.3>A (236), L1.2>A (237), D27>A (267), P114>A (331) (233-342), CH3 Y5>C (351), D12 (358), L14 (360), T22>S (368), L24>A (370), Y86>V (409) (343-447), CHS (448-449)) (120-449)], (222-220')-disulfide with light chain common L-kappa (L') (1'-220') [V-KAPPA (Homo sapiens IGKV4-1*01 (94.1%) -IGKJ4*01 (90.9%) V124>L (110'), CDR-IMGT [12.3.9] (27'-38'.56'-58'.95'-103')) (1'-113') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (159'), V101 (197')) (114'-220')]; heavy chain VH-G1(CH1-5h) anti-GPRC5D -scFvhl anti-CD3E -G1(h-CH2-CH3) (knob) (H'') (1''-704'') [VH-G1(CH1-5h) chimeric anti-GPRC5D (1''-222'') [VH Musmus/Homsap (Mus musculus IGHV1-47-14*01 (83.7%) -(IGHD) -IGHJ3*01 (91.7%) A128>S (119'')/Homo sapiens IGHV1-46*01 (78.6%) -(IGHD) -IGHJ4*01 (100%), CDR -IMGT [8.8.12] (26''-33''.51''-58''.97''-108'')) (1''-119'') -Homo sapiens IGHG1*01 CH1-5h, G1m17,1 CH1 K120 (CH1 K120 (216'') (120''-217''), hinge 1-5 (218''-222'')) (120''-222'')] -scFvhl anti-CD3E (223''-471'') [VH Musmus/Homsap (Mus musculus IGHV10-1*02 (90.8%) -(IGHD) -IGHJ4*01 (91.7%) S123>T (342'')/Homo sapiens IGHV3-73*01 (90.0%) -(IGHD) -IGHJ6*01 (100%), CDR -IMGT [8.10.16] (248''-255''.273''-282''.321''-336'')) (223''-347'') -15-mer tris(tetraglycyl-seryl) linker (348''-362'') -V-LAMBDA Musmus/Homsap (Mus musculus IGLV1*01 (82.3%) -IGLJ1*01 (100%)/Homo sapiens IGLV7-46*01 (78.9%) -IGLJ3*02 (100%), CDR -IMGT [9.3.9] (388''-396''.414''-416''.453''-461'')) (363''-471'') ] -1-mer glycyl linker (472'') -G1(h-CH2-CH3) Homo sapiens IGHG1*01 h-CH2-CH3-CHS, G1m17,1 CH3 D12, L14, 15-G1v37 h S5, 1-G1v66 CH2 A27, 6-G1v14-4 CH2 A1.3, A1.2, A114, 14-G1v74 CH3 C10, 14-G1v32 CH3 W22 (knob) (hinge 1-15 C5>S (477'') (473''-487''), CH2 L1.3>A (491''), L1.2>A (492''), D27>A (522''), P114>A (586'') (488''-597''), CH3 S10>C (611''), D12 (613''), L14 (615''), T22>W (623'') (598''-702''), CHS (703''-704'')) (473''-704'')]], (222''-220''')-disulfide with light chain common L-kappa (L''') (1'''-220''') [V-KAPPA (Homo sapiens IGKV4-1*01 (94.1%) -IGKJ4*01 (90.9%) V124>L (110'''), CDRIMGT [12.3.9] (27'''-38'''.56'''-58'''.95'''-103''')) (1'''-113''') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (159'''), V101 (197''')) (114'''-220''')]; dimer (228-483'':231-486'':351-611'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa
